Overview

The Repatriation Medical Authority Instrument No. 76 of 2011 amends the Veterans' Entitlements Act 1986, specifically Statement of Principles Instrument No. 34 of 2008, concerning benign neoplasm of the eye and adnexa. The Instrument introduces amendments to address the link between benign neoplasm of the eye and adnexa and exposure to ionising radiation, a significant issue for veterans who may have been exposed to such radiation during their service. The Authority, under the VEA, determined this Instrument following an investigation advertised in the Government Notices Gazettes, inviting submissions from relevant organisations and experts. The amendments aim to refine the criteria for assessing claims related to these conditions by replacing and removing certain factors and definitions, enhancing the accuracy and fairness of veterans' entitlements assessments. This legislative instrument reflects the commitment to ensuring that veterans receive appropriate compensation for conditions arising from their service, aligning with the broader policy objective of the VEA to support and compensate veterans for service-related health issues.

Scope and Application

The Repatriation Medical Authority Instrument No. 76 of 2011 amends Statement of Principles Instrument No. 34 of 2008, which pertains to benign neoplasm of the eye and adnexa, by making several key changes. These changes include the replacement of an existing factor concerning radiation exposure with a new factor specifically referencing "ionising radiation", the deletion of a redundant factor that is now encapsulated within the new ionising radiation factor, the replacement of the definition of "cumulative equivalent dose", and the removal of the definitions of "a course of therapeutic radiation" and "atomic radiation". This Instrument applies to veterans and service personnel affected by benign neoplasm of the eye and adnexa, as well as their dependants, who are seeking benefits under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. The amendments are effective from a date specified in accordance with the Legislative Instruments Act 2003. The Repatriation Medical Authority conducted an investigation into the condition, advertising its intentions in the Government Notices Gazettes and soliciting submissions from relevant stakeholders, although no submissions were received. The Authority's decision concludes the investigation as advertised in the Gazettes.

Key Provisions

The Repatriation Medical Authority Instrument No. 76 of 2011 amends Statement of Principles Instrument No. 34 of 2008 concerning benign neoplasm of the eye and adnexa, as specified under sections 196B(3) and 196B(8) of the Veterans’ Entitlements Act 1986 (VEA). This legislative amendment introduces significant changes to the criteria for assessing benign neoplasm of the eye and adnexa, primarily by replacing and refining existing factors. Specifically, factor 6(a)(i) is replaced with a new factor concerning "ionising radiation", which replaces the need for the previous sub-factor 6(a)(ii). Additionally, the definition of "cumulative equivalent dose" in clause 9 is revised, and the definitions of "a course of therapeutic radiation" and "atomic radiation" are deleted from clause 9. These changes are designed to more accurately reflect the current medical understanding and evidence regarding the condition in question. The obligations imposed by this Instrument on the parties it governs primarily involve ensuring that the updated criteria are applied correctly in assessments and claims related to benign neoplasm of the eye and adnexa. The Authority is tasked with ensuring that the amendments reflect the most current medical and scientific evidence, which involves careful consideration of submissions and expert opinions during the investigation phase. Although no submissions were received for this particular Instrument, the process requires the Authority to consider any relevant submissions from stakeholders, including the Repatriation Commission and other organisations and experts specified under section 196E of the VEA. The Authority must also ensure that any changes to the Statement of Principles are clearly communicated to all relevant parties and that the updated criteria are applied consistently in future assessments. Failure to comply with the provisions of this Instrument could potentially result in incorrect or unfair assessments of veterans' claims related to benign neoplasm of the eye and adnexa. While the Instrument itself does not explicitly detail offences, penalties, or civil/criminal consequences for breaches, the broader legislative framework under which it operates, including the VEA and the Legislative Instruments Act 2003, would apply. Breaches of these Acts could lead to various legal repercussions, including administrative penalties, judicial review, or other legal actions as deemed appropriate by the relevant authorities. The Authority is responsible for ensuring that its decisions and the application of this Instrument are in accordance with the law, thereby avoiding any potential legal complications for affected parties.